Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / MRNA
Stock rating · Biological Products, (No Diagnostic Substances)
Moderna, Inc. (MRNA) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Moderna, Inc. 65 out of 100 (Promising). Its highest factor score is earnings track record at 92, and its lowest is business quality at 23.
MELANY ratingRated 2026-10-06MRNA · composite score
About Moderna, Inc.
Moderna is a commercial-stage biotech founded in 2010 that went public in December 2018. Its mRNA technology was validated by its covid vaccine, authorized in the US in December 2020. As of August 2025 the company had 35 mRNA candidates in clinical studies, spanning infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why MRNA scores 65/100
MRNA's 8 factor scores run from 23 to 92, and 3 of them sit above its composite of 65. Here is how MRNA breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +45.0% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +30%
- Earnings in 30 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 30 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How MRNA compares
As of October 7, 2026, Moderna, Inc. ranks 10th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for MRNA
- Operating margin -558%, currently unprofitable on a trailing basis
- Trading near 52-week high, limited upside without new positive catalyst
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Moderna, Inc. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 61/100 for strength. Theme strength feeds MRNA's momentum and catalyst factors above.
MRNA trade plan (Pro)
MELANY has a full position plan for Moderna, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates MRNA
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Moderna, Inc.'s 65/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MRNA
Is Moderna, Inc. (MRNA) a buy?
As of 2026-10-06, MELANY rated Moderna, Inc. Promising with a composite score of 65/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Moderna, Inc.'s MELANY score?
Moderna, Inc. (MRNA) has a MELANY composite score of 65/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the MRNA stock rating calculated?
MELANY scores MRNA from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Moderna, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Moderna, Inc. (MRNA) Promising with a composite of 65/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MRNA stock price forecast?
MELANY does not publish price targets or forecasts for MRNA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 65/100 across eight factors for Moderna, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is MRNA stock overvalued or undervalued?
MELANY's valuation factor currently reads 40/100 for Moderna, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MRNA's read.
What price should I buy MRNA at?
Rather than chasing the current price, MELANY computes a smart entry zone for MRNA: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying MRNA stock?
The top risks MELANY currently flags for Moderna, Inc.: Operating margin -558%, currently unprofitable on a trailing basis; Trading near 52-week high, limited upside without new positive catalyst; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Moderna, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 23/100 for Moderna, Inc., and earnings track record, at 92/100. The 65/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MRNA stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 84/100 for MRNA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MRNA rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores MRNA continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, MRNA included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.